Matias A. Avila

Prof. Matias A. Avila

1. Hepatology Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SLShelly C. Lu
Shelly C. Lu
LALuis Alvarez
Luis Alvarez
ZHZong-Zhi Huang
Zong-Zhi Huang
LCLixin Chen
Lixin Chen
WAWei An
Wei An
JMJose M Mato
Jose M Mato
Liver-specific and nonliver-specific methionine adenosyltransferases (MATs) are products of two genes, MAT1A and MAT2A , respectively, that catalyze the formation of S -adenosylmethionine (AdoMet), the principal biological methyl donor. Mature liver expresses MAT1A , whereas MAT2A is expressed in extrahepatic tissues and is induced during liver growth and dedifferentiation. To examine the influence of MAT1A on hepatic growth, we studied the effects of a targeted disruption of the murine MAT1A gene. MAT1A mRNA and protein levels were absent in homozygous knockout mice. At 3 months, plasma methionine level increased 776% in knockouts. Hepatic AdoMet and glutathione levels were reduced by 74 and 40%, respectively, whereas S -adenosylhomocysteine, methylthioadenosine, and global DNA methylation were unchanged. The body weight of 3-month-old knockout mice was unchanged from wild-type littermates, but the liver weight was increased 40%. The Affymetrix genechip system and Northern and Western blot analyses were used to analyze differential expression of genes. The expression of many acute phase-response and inflammatory markers, including orosomucoid, amyloid, metallothionein, Fas antigen, and growth-related genes, including early growth response 1 and proliferating cell nuclear antigen, is increased in the knockout animal. At 3 months, knockout mice are more susceptible to choline-deficient diet-induced fatty liver. At 8 months, knockout mice developed spontaneous macrovesicular steatosis and predominantly periportal mononuclear cell infiltration. Thus, absence of MAT1A resulted in a liver that is more susceptible to injury, expresses markers of an acute phase response, and displays increased proliferation.

1 January 2002 in The FASEB Journal
Verified
Journal Article
Closed access
JMJose M Mato
Jose M Mato
FCFernando Corrales
Fernando Corrales
SLShelly C. Lu
Shelly C. Lu
Matias A. AvilaMatias A. Avila
Matias A. Avila

26 February 2009 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Carmen BerasainCarmen Berasain
Carmen Berasain
JCJ. Castillo
J. Castillo
MPM.J. Perugorria
M.J. Perugorria
MLM.U. Latasa
M.U. Latasa
JPJ. Prieto
J. Prieto
Matias A. AvilaMatias A. Avila
Matias A. Avila

26 June 2006 in Oncogene
Verified
Journal Article
Open access
PDF file
Matias A. AvilaMatias A. Avila
Matias A. Avila
Carmen BerasainCarmen Berasain
Carmen Berasain
BSBruno Sangro
Bruno Sangro
JPJ Prieto
J Prieto
Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is often diagnosed at an advanced stage when most potentially curative therapies such as resection, transplantation or percutaneous and transarterial interventions are of limited efficacy. The fact that HCC is resistant to conventional chemotherapy, and is rarely amenable to radiotherapy, leaves this disease with no effective therapeutic options and a very poor prognosis. Therefore, the development of more effective therapeutic tools and strategies is much needed. HCCs are phenotypically and genetically heterogeneous tumors that commonly emerge on a background of chronic liver disease. However, in spite of this heterogeneity recent insights into the biology of HCC suggest that certain signaling pathways and molecular alterations are likely to play esscntial roles in HCC development by promoting cell growth and survival. The identification of such mechanisms may open new avenues for the prevention and treatment of HCC through the development of targeted therapies. In this review we will describe the new potential therapeutic targets and clinical developments that have emerged from progress in the knowledge of HCC biology, In addition, recent advances in gene therapy and combined cell and gene therapy, together with new radiotherapy techniques and immunotherapy in patients with HCC will be discussed.

1 April 2014 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
Carmen BerasainCarmen Berasain
Carmen Berasain
Matias A. AvilaMatias A. Avila
Matias A. Avila

1 December 2000 in Journal of Hepatology
Verified
Journal Article
Closed access
Matias A. AvilaMatias A. Avila
Matias A. Avila
Carmen BerasainCarmen Berasain
Carmen Berasain
LTLuis Torres
Luis Torres
AMAntonio Martín-Duce
Antonio Martín-Duce
FCFernando Corrales
Fernando Corrales
JMJose M Mato
Jose M Mato